Clinical trials: Pathologic Response
Acute Wound
Cleanser for Acute Wounds
The proposed study will be a prospective trial of management of acute traumatic wounds (less than 24 hours from injury and without previous intervention aside from a dressing for coverage).
- Trial name
- NCT05422144
- Testing
- Antimicrobial Skin & Wound Cleanser (AWC), Antimicrobial Wound Gel (AWG)
- Where
- United States
- Sponsor
- Rochal Industries LLC
Chronic Myeloid Leukemia
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
This study is constituted of two stage: Treatment-Free Remission 1 (TFR1) stage and Treatment-Free Remission 2 (TFR2) stage. The purpose of the TFR1 stage is to assess the effect of nilotinib reduced to half the standard dose for…
- Trial name
- DANTE (NCT03874858)
- Testing
- Nilotinib, Asciminib
- Where
- 26 sites in Italy
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Sepsis, Severe Sepsis
TRIAGE: TRIage of Sepsis At emerGency dEpartment
Sepsis is a serious systemic disease defined as a combination of Systemic Inflammation Response Syndrome (SIRS) plus a confirmed or suspected infection.
- Trial name
- TRIAGE (NCT02739152)
- Where
- 14 sites in Belgium, France
- Volunteers
- 602 people
- Sponsor
- BioMérieux
Hepatitis C, Chronic
Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)
This is a controlled, randomized, parallel-groups, open-label, multinational study designed to evaluate the efficacy and safety of PEG-Intron® (pegylated interferon alfa-2b) plus Rebetol® (ribavirin) in subjects with chronic…
- Trial name
- NCT00265395
- Testing
- Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®), Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 1,428 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Biliary Cholangitis
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy
Study of Saroglitazar Magnesium for PBC Patients with Incomplete Response or Intolerant to UDCA Therapy
- Trial name
- EPICS-IV (NCT07424677)
- Testing
- Saroglitazar Magnesium 1 mg
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Zydus Therapeutics Inc.
Neoplasm Metastasis, Neoplasm Recurrence
PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy
The objectives of this Phase I/II study are: 1. To find out the maximum tolerated dose (MTD) of PG2 in patients with advanced malignancy receiving chemotherapy and to define a "Study Dose" for Phase II. 2.
- Trial name
- NCT01696565
- Testing
- PG2
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- PhytoHealth Corporation
Sepsis
Effect of SRT2379 on Endotoxin-Induced Inflammation
SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic inflammation induced by intravenous injection of lipopolysaccharide (LPS) in mice.
- Trial name
- NCT01262911
- Testing
- SRT2379
- Where
- Netherlands
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Sirtris, a GSK Company
Candidemia
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
The purpose of this study is to assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Candida Assay.
- Trial name
- DIRECT (NCT01525095)
- Where
- 5 sites in United States
- Volunteers
- 700 people
- Sponsor
- T2 Biosystems
Severe Sepsis, Septic Shock
Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction
The trial enrolls patients with early severe sepsis or septic shock displaying at least one newly developed organ dysfunction and showing clinical evidence of pulmonary or abdominal infection.
- Trial name
- SCIENS (NCT02246595)
- Testing
- CaCP29
- Where
- 11 sites in Germany
- Volunteers
- 72 people
- Sponsor
- InflaRx GmbH
Hepatitis B, Chronic
To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)
This study is to evaluate the antiviral efficacy of add-on adefovir to telbivudine in non-responders to telbivudine monotherapy after 24 and 36 initial weeks.
- Trial name
- NCT00537537
- Testing
- Telbivudine
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Prediabetes, Hypertension
Fasting Predictors of OGTT and MMTT Response
1. To develop a database containing matched information from dynamic tests of postprandial glycemic control (OGTT or MMTT), results of a broad panel of fasting biomarkers, and clinical information related to diabetes risk obtain…
- Conditions
- Prediabetes, Hypertension, Obesity, Cardiovascular Disease
- Trial name
- NCT01998867
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Health Diagnostic Laboratory, Inc.
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with…
- Trial name
- NCT00454779
- Testing
- Cisplatin, Panitumumab, Docetaxel
- Where
- 114 sites in United States, Austria and 7 more
- Volunteers
- 113 people
- Sponsor
- Amgen
Candidiasis
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States…
- Trial name
- NCT00037219
- Testing
- Anidulafungin, VER002
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Pfizer
Sepsis, Septic Shock
Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis
The purpose of this prospective, non-interventional, multi-centre clinical study is to assess the clinical validity of the Heparin Binding Protein (HBP) assay for indicating the presence, or outcome, of severe sepsis (including…
- Conditions
- Sepsis, Septic Shock, Sepsis With Acute Organ Dysfunction
- Trial name
- NCT03113721
- Where
- 5 sites in United States
- Volunteers
- 571 people
- Sponsor
- Axis Shield Diagnostics Ltd
Endometriosis
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
The main objective for this study is to assess the efficacy and dose-response relationship of ASP1707 in reduction of endometriosis associated pelvic pain.
- Trial name
- NCT01767090
- Testing
- ASP1707, Leuprorelin acetate
- Where
- 85 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 912 people
- Sponsor
- Astellas Pharma Europe B.V.
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Hepatitis C, Chronic, Insulin Resistance
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1.
- Trial name
- NCT00493805
- Testing
- Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC
Sepsis
Discharge Readmission Analysis and Management in Sepsis (DReAMS-2)
This is an adaptive platform. This study is being done to collect information that will help us identify trends in patients with sepsis and other health conditions being readmitted into hospitals within 30 days of being…
- Trial name
- NCT06099756
- Where
- 3 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Measure Labs, Inc.
Leukemia
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
The purpose of this clinical research study is to compare the rate of complete cytogenetic response of dasatinib to imatinib therapy at 6 months after randomization in chronic phase CML patients.
- Trial name
- NCT00362466
- Testing
- Dasatinib, Imatinib
- Where
- 45 sites in United States
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
Severe Sepsis, Coagulopathy
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
- Trial name
- NCT01598831
- Testing
- ART-123
- Where
- 161 sites in United States, Argentina and 22 more
- Volunteers
- 816 people
- Sponsor
- Asahi Kasei Pharma America Corporation